AEON
Income statement / Annual
Last year (2024), AEON Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, AEON Biopharma, Inc.'s net income was $42.01 M.
See AEON Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.52 M |
$3.36 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.52 M
|
$3.36 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
1
|
1
|
| Research and Development Expenses |
$14.18 M
|
$33.05 M
|
$34.75 M
|
$25.73 M
|
$7.32 M
|
$4.81 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.64 M
|
$19.79 M
|
$13.68 M
|
$11.15 M
|
$11.59 M
|
$46.04 M
|
| Other Expenses |
-$100.81 M
|
$295.25 M
|
$0.00
|
$28.97 M
|
$0.00
|
$6.47 M
|
| Operating Expenses |
-$72.99 M
|
$348.09 M
|
$48.43 M
|
$65.85 M
|
$18.91 M
|
$57.32 M
|
| Cost And Expenses |
-$72.99 M
|
$348.09 M
|
$48.43 M
|
$65.85 M
|
$18.91 M
|
$57.32 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$720.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$15.00 K
|
$7.47 M
|
| Depreciation & Amortization |
$97.00 K
|
$99.00 K
|
$68.00 K
|
$3.00 K
|
$875.00 K
|
$875.00 K
|
| EBITDA |
-$27.73 M |
-$52.74 M |
-$48.36 M |
-$36.88 M |
-$15.51 M |
-$47.50 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-6.16
|
-14.15
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-6.51
|
-16.08
|
| Total Other Income/Expenses Net |
-$30.98 M
|
-$36.55 M
|
-$4.13 M
|
$10.21 M
|
-$16.53 M
|
$199.64 M
|
| Income Before Tax |
$42.01 M
|
-$384.63 M
|
-$52.56 M
|
-$55.64 M
|
-$32.91 M
|
$145.67 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-13.07
|
43.39
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$14.65 M
|
| Net Income |
$42.01 M
|
-$384.63 M
|
-$52.56 M
|
-$55.64 M
|
-$32.91 M
|
$172.92 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-13.07
|
51.51
|
| EPS |
77.74 |
-4.99 |
-27.25 |
-31.73 |
-547.6 |
1495.96 |
| EPS Diluted |
72.93 |
-4.99 |
-27.25 |
-31.73 |
-547.6 |
1481.04 |
| Weighted Average Shares Out |
$575.00 K
|
$77.07 M
|
$1.93 M
|
$1.75 M
|
$60.00 K
|
$116.00 K
|
| Weighted Average Shares Out Diluted |
$575.95 K
|
$77.07 M
|
$1.93 M
|
$1.75 M
|
$91.62 K
|
$92.30 K
|
| Link |
|
|
|
|
|
|
